KALA BIO, Inc. (KALA)
(Delayed Data from NSDQ)
$6.30 USD
+0.12 (1.94%)
Updated Apr 26, 2024 03:58 PM ET
3-Hold of 5 3
F Value B Growth A Momentum C VGM
Price, Consensus and EPS Surprise
KALA 6.30 +0.12(1.94%)
Will KALA be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for KALA based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for KALA
Does KALA BIO (KALA) Have the Potential to Rally 152.83% as Wall Street Analysts Expect?
KALA BIO (KALA) Reports Q3 Loss, Misses Revenue Estimates
KALA: What are Zacks experts saying now?
Zacks Private Portfolio Services
Dermata (DRMA) Gains on Positive FDA Response for Acne Candidate
VYNE Gains on Preclinical Data for IPF Candidate
Madrigal (MDGL) Gains on NASH Treatment's Breakthrough Therapy Tag
Other News for KALA
Buy Rating on Kala Pharmaceuticals Amidst Positive Clinical Developments and Strong Financial Position
Kala Pharmaceuticals price target lowered by $1 at H.C. Wainwright, here's why
KALA Stock Earnings: Kala Pharmaceuticals Beats EPS for Q4 2023
KALA BIO Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update
Kala Pharmaceuticals GAAP EPS of -$3.18 beats by $0.44